London Stock Exchange is pleased to welcome Quantum Pharma Plc
London Stock Exchange is pleased to welcome Quantum Pharma Plc (“Quantum”, the “Company” or the “Group”) to AIM on 11 December 2014 (symbol QP).
Quantum Pharma is a growing manufacturer, supplier and service provider to pharmaceutical wholesalers, retail pharmacy, hospitals, pharmaceutical companies, homecare and care home markets. Quantum operates through five business units: Quantum Pharmaceutical,
U L Medicines, Colonis, Biodose and Quantum Aseptics. The Group’s core business is the manufacture, procurement and supply to major UK pharmacy chains, wholesalers and hospitals of Specials and Special Obtains. Specials are medicines which are not licensed for general manufacture, which are prescribed for a specific patient need and which are manufactured or procured, under an MHRA licence. Special Obtains are medicines and medicinal products that are difficult for pharmacies to source from a mainline pharmaceutical wholesaler.
Quantum’s overall strategy is to become the UK’s leading provider of niche pharmaceuticals and services to the pharmacy, hospital, wholesale, home care and care home markets, and to supply these medicines with the highest available service levels and delivery solutions.
The Company, together with the Zeus Capital, successfully raised £106.1 million (before expenses) by placing 106.1 million vendor and new ordinary shares with investors at a placing price of 100 pence per ordinary share. Quantum’s market capitalisation on admission, based on the placing price, is approximately £125 million.
Andrew Scaife, Chief Executive Officer of Quantum Pharma plc, said: “Opening the stock market today is a great honour and indeed a milestone event for the whole team at Quantum. We look forward to executing our strategy as we move to the next stage of our development as a publicly quoted company.”
Zeus Capital Limited acted as Nominated Adviser and Broker to the Company, with Muckle LLP and KPMG LLP acting as legal adviser and reporting accountant to the Company respectively. Addleshaw Goddard LLP acted as legal advisers to the Nominated Adviser. Abchurch Communications Limited provided financial PR advice.